Effects of heterogeneous collagen-based formulation on growth and metastasis of B16-F1 melanoma in mice: an experimental, cohort, controlled study

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: Defects after melanoma resection require effective and minimally invasive methods for their management to be developed. Current techniques have several limitations and do not always provide a satisfactory aesthetic outcome. Thus, new techniques, including gel injection, should be developed. Рeterogeneous collagen-based formulation is one of the promising options. It has shown its effectiveness in enhancement of wound healing; however, there is no data on its interaction with tumor cells.

AIM: The study aimed to assess the interaction and effect of heterogeneous collagen-based formulation on B16-F1 melanoma in an experiment.

METHODS: The experiment was conducted on laboratory animals (mice) divided into groups to receive injections of heterogeneous collagen-based formulation and 0.9% sodium chloride solution. Laboratory animals were monitored for 20 days, weight and tumor size were measured regularly. The animals were sacrificed, and the primary tumor, lymph nodes, and lungs were sampled for histological examination.

RESULTS: An analysis of the growth rate, metastasis to the lymph nodes and lungs revealed no significant difference between the study and control groups. Tumor histology also did not differ; however, the examination found the injected heterogeneous collagen-based formulation in several samples from unoperated animals.

CONCLUSION: The B16-F1 melanoma model showed no effect of the heterogeneous collagen-based formulation on primary tumor growth and metastasis. This result suggests that this material is potentially safe, which is an important step in the search and development of new oncological reconstructions techniques.

About the authors

Dmitry V. Davydov

National Medical Research Radiological Center

Email: d-davydov3@yandex.ru
ORCID iD: 0000-0001-5506-6021
SPIN-code: 1368-2453

MD, Dr. Sci. (Medicine), Professor; P. Hertsen Moscow Oncology Research Institute

Russian Federation, Moscow

Maksim O. Karpechkin

National Medical Research Radiological Center

Author for correspondence.
Email: maxim.karpechkin@yandex.ru
ORCID iD: 0000-0001-8817-2736
SPIN-code: 9058-4420

P. Hertsen Moscow Oncology Research Institute

Russian Federation, Moscow

Natalya B. Morozova

National Medical Research Radiological Center

Email: maxim.karpechkin@yandex.ru
ORCID iD: 0000-0002-7159-805X
SPIN-code: 1286-6518

MD, Cand. Sci. (Biology); P. Hertsen Moscow Oncology Research Institute

Russian Federation, Moscow

Varvara A. Khokhlova

National Medical Research Radiological Center

Email: nostocus@yandex.ru
ORCID iD: 0000-0002-0339-2068
SPIN-code: 9647-7576

P. Hertsen Moscow Oncology Research Institute

Russian Federation, Moscow

Nadezhda V. Perova

Biomir-Service

Email: maxim.karpechkin@yandex.ru
ORCID iD: 0000-0003-2215-8944
SPIN-code: 7121-0988

MD, Dr. Sci. (Biology)

Russian Federation, Krasnoznamensk

Anna O. Nemechkina

National Medical Research Radiological Center

Email: maxim.karpechkin@yandex.ru
ORCID iD: 0009-0006-0382-5675
SPIN-code: 9387-5218

P. Hertsen Moscow Oncology Research Institute

Russian Federation, Moscow

References

  1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. doi: 10.3322/caac.21834
  2. Kaprin AD, Starinsky VV, Shakhzadova AO, editors. The state of oncological care for the population of Russia in 2022. Moscow: P.A. Herzen Moscow Oncology Research Institute — branch of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation; 2022. (In Russ.)
  3. Polyakov AP, Rebrikova IV, Mordovskiy AV. Current treatment strategy for resectable scalp and neck melanoma. Head and Neck Tumors. 2021;11(2):50–56. doi: 10.17650/2222-1468-2021-11-2-50-56 EDN: VQMXEL
  4. Shubina AS, Ufimtseva MA, Petkau VV, et al. To the question of melanoma of rare localizations. Russian Journal of Clinical Dermatology and Venereology. 2020;19(6):868–872. doi: 10.17116/klinderma202019061868 EDN: GRCXZS
  5. Moncrieff MD, Thompson JF, Quinn MJ, Stretch JR. Reconstruction after wide excision of primary cutaneous melanomas: part I — the head and neck. Lancet Oncol. 2009;10(7):700–708. doi: 10.1016/S1470-2045(09)70116-0
  6. Celoria V, Rosset F, Pertusi G, et al. Advantages of mohs surgery in the treatment of NMSC in the head and neck district. J Clin Med. 2025;14(13):4732. doi: 10.3390/jcm14134732
  7. Meaike JD, Dickey RM, Killion E, et al. Facial skin cancer reconstruction. Semin Plast Surg. 2016;30(3):108–121. doi: 10.1055/s-0036-1584821
  8. Moncrieff MD, Spira K, Clark JR, et al. Free flap reconstruction for melanoma of the head and neck: indications and outcomes. J Plast Reconstr Aesthet Surg. 2010;63(2):205–212. doi: 10.1016/j.bjps.2008.11.027
  9. Perova NV, Porunova YuV, Urjash VF, et al. Biodegraded collagen-contain sferogel tm matrix for bioartificial bodies. Inorganic Materials: Applied Research. 2004;(2):52–59. EDN: RXGHEH
  10. Porunova YuV. Development and preclinical study of a collagen-containing matrix for cell transplantation [dissertation]. Moscow; 2004. (In Russ.)
  11. Zhang D, Wu X, Chen J, Lin K. The development of collagen based composite scaffolds for bone regeneration. Bioact Mater. 2017;3(1):129–138. doi: 10.1016/j.bioactmat.2017.08.004
  12. Sipkin AM, Modina TN, Gnatyuk ND, Okshin DU. Collagen-containing osteoplastic materials: A review. Clinical Dentistry (Russia). 2023;26(4): 152–159. doi: 10.37988/1811-153X_2023_4_152 EDN: IIGWBY
  13. Manturova NE, Stenko AG, Petinati YaA, et al. Injectable collagen in correction of age-related skin changes: experimental and clinical parallels. Bulletin of RSMU. 2019;(1):78–85. doi: 10.24075/vrgmu.2019.010 EDN: MBGULA
  14. Mironov AN, editor. Guidelines for conducting preclinical studies of medicinal products. Part II. Moscow: Grif i K; 2012. (In Russ.)

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2025 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).